Splenic Cytology Shows Limited Agreement With Histopathology

Home / Hemangio Journal / Splenic Cytology Shows Limited Agreement With Histopathology

A retrospective study from the University of Georgia College of Veterinary Medicine compared cytology and histopathology results in dogs with splenic masses or nodular lesions, finding only poor to fair agreement between the two when distinguishing neoplastic from nonneoplastic disease.

Splenic masses may be discovered on physical examination, in the setting of hemoperitoneum, or incidentally on imaging. Imaging can confirm a mass arises from the spleen, but it cannot provide a pathologic diagnosis, and histopathology following splenectomy remains the gold standard. Without a presurgical diagnosis, veterinarians are limited to the double two-thirds rule when guiding families: two-thirds of splenic masses are malignant, and two-thirds of those are hemangiosarcoma. The authors note that the presence or absence of hemoperitoneum should factor into how this rule is applied, as dogs with ruptured masses are more likely to have malignancy, while incidentally discovered, nonruptured masses are more often benign.

Fine needle aspiration is frequently used as a preoperative tool because it is fast, minimally invasive, and cost-effective. However, previous studies comparing splenic cytology to histopathology reported widely variable agreement, and all of them included dogs with diffuse splenomegaly alongside splenic masses. The authors note that the specific influence of mass-like lesions on the accuracy of splenic cytology had not previously been investigated.

Cytology and histopathology agreed on a neoplastic versus nonneoplastic diagnosis in 55% of dogs. When lesions classified as “possibly neoplastic” on cytology were counted as neoplastic, agreement rose to 67%. A neoplastic cytologic result proved more reliable than a nonneoplastic one: 71% of lesions called neoplastic or possibly neoplastic on cytology were confirmed on histopathology, compared with 63% of those called nonneoplastic. In one dog, both methods identified neoplasia, but cytology suggested sarcoma while histopathology confirmed lymphoma, a discrepancy that could change the prognosis and influence a family’s decision about surgery.

The authors attribute these limitations to the nature of cytology itself, which offers good cellular detail but relies on focal sampling and cannot capture tissue architecture. In dogs with multiple splenic nodules, the aspirated lesion may also not be the same one evaluated on histopathology.

The study has several limitations. Only 33 of 867 reviewed dogs met inclusion criteria, and the design was retrospective. Ruptured splenic masses were underrepresented, since dogs presenting with hemoperitoneum typically proceed directly to surgery without a preoperative aspirate. Because hemangiosarcoma is more common in that population, the authors acknowledge that nonhemangiosarcoma lesions may be overrepresented in their cohort. Slide review also relied on archived samples, often a single slide per case.

The clinical takeaway is clear: a nonneoplastic cytologic result does not exclude neoplasia, while a neoplastic result is more often confirmed and warrants further investigation with histopathology.